WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > HQSI (Healthcare Quality Strategies, Inc)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
MedTech
Aanika Biosciences | December 01, 2021
Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accurac...
Cell and Gene Therapy
Antengene | June 28, 2022
Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1...
Research
Nutrition Technologies | September 19, 2022
On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...
Stemcyte | March 23, 2022
On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorder...
MedTech, Industrial Impact
Whitepaper
Medical, Industry Outlook
Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE